feedback

Course Director

Robert Anders, MD, PhD
Robert Anders, MD, PhD

Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Faculty

Julie R. Brahmer
Julie R. Brahmer, MD, MSc

Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Christopher D. Gocke
Christopher D. Gocke, MD

Johns Hopkins University School of Medicine
Baltimore, Maryland

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC
Credit Amount:1.5 Credits
Release Date:2019-May-01
Expiration Date:2020-Apr-30
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of solid tumors and hematologic malignancies. Reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit. Testing for programmed death-ligand 1 (PD-L1) expression and the presence of DNA mismatch repair deficiencies (dMMR) or high levels of microsatellite instability (MSI-H) should presently be routinely done in oncology and pathology practice in alignment with the latest recommendations and indications. Assessment of tumor mutational burden (TMB) is also showing great promise as a new and distinct predictor of benefit from cancer immunotherapies. Other novel biomarkers are undergoing investigations as well.

How can pathologists ensure that immuno-oncology biomarker testing is carried out according to best practices, and collaborate with oncologists and other members of the cancer care team in interpreting the results to guide therapeutic decisions for patients with cancer? In this activity, based on a recent CME/MOC/CC-certified symposium held during the 2019 Annual Meeting of the United States and Canadian Academy of Pathology (USCAP) held in National Harbor, Maryland, a panel of experts discuss the latest clinical advances with cancer immunotherapies and the research underway to further refine biomarker testing and maximize the use of checkpoint inhibitors and combinations across a broad spectrum of malignancies.

Upon completion of this activity, participants should be better able to:
  • Characterize the efficacy/safety profiles and clinical roles of the current and emerging immunotherapies and combinations across the spectrum of solid and liquid cancers
  • Describe evidence supporting the use of PD-L1, MMR/MSI, TMB, and other promising biomarkers as predictors of benefit from cancer immunotherapies
  • Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies, assays, cut-points, and other nuances
  • Assess the potential role of novel strategies and technologies being evaluated as part of cancer immunotherapy biomarker development for predictive and other purposes
  • Implement best practices for cancer immunotherapy biomarker testing in community and academic settings based on the latest evidence and recommendations
  • Establish effective strategies for interdisciplinary collaboration among pathologists, oncologists, and other key professionals regarding biomarker testing and interpretation to guide decisions about the use of cancer immunotherapies and combinations in patients with cancer

Target Audience

This activity has been designed to meet the educational needs of pathologists, oncologists, and other healthcare professionals interested in precision cancer immunotherapy and immunotherapy biomarkers, and/or involved in cancer immunotherapy biomarker testing and treatment individualization.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CC credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: May 01, 2019 - April 30, 2020
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Other PVI associates who are in a position to have control over the content of this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CC activity during the past 12 months.

The associates of the Medical Learning Institute, Inc., the accredited provider for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CC activity during the past 12 months.

Course Director and Moderator

Robert Anders, MD, PhD
Associate Professor of Pathology
Co-Director, Tumor Microenvironment Lab
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Robert Anders, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Adaptive Biotechnologies; AstraZeneca; Bristol-Myers Squibb and Merck & Co., Inc.
Grant/Research Support from Bristol-Myers Squibb; Five Prime Therapeutics, Inc. and FLX Bio, Inc.

Robert Anders, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies and immuno-oncology biomarkers.

Faculty

Julie R. Brahmer, MD, MSc
Professor of Oncology
Director of the Thoracic Oncology Program
Director of the Sidney Kimmel Cancer Center at Johns Hopkins Bayview
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Julie R. Brahmer, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Bristol-Myers Squibb; Celgene Corporation; Eli Lilly and Company; Genentech, Inc.; Janssen Oncology; and Merck & Co., Inc.
Grant/Research Support from Bristol-Myers Squibb; MedImmune/AstraZeneca; and Merck & Co., Inc.

Julie R. Brahmer, MD, MSc, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies and immuno-oncology biomarkers.

Christopher D. Gocke, MD
Associate Professor of Pathology and Oncology
Director, Division of Molecular Pathology
Co-Director, Johns Hopkins Genomics
Johns Hopkins University School of Medicine
Baltimore, Maryland

Christopher D. Gocke, MD, has no financial interests/relationships or affiliations in relation to this activity.

Christopher D. Gocke, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies and immuno-oncology biomarkers.

Content Reviewers

Jim Zhai, MD, FCAP, has no financial interests/relationships or affiliations in relation to this activity.

Tracy L. Greene, MSN, RN, FNP-C, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Kristin Tomlinson, PhD
PVI, PeerView Institute for Medical Education

Kristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC/CC activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Continuing Certification Statement

The activity titled “Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Implications for Pathologists at the Forefront of the Emerging Precision Immuno-Oncology Era” has been registered to offer 1.5 Lifelong Learning (Part II) credits in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Participation information will be shared with ABPath through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Providership


This CME/MOC/CC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent educational grants from AstraZeneca, Bristol-Myers Squibb, Foundation Medicine Inc., and Merck & Co., Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC/CC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.